Mechlorethamine, vincristine, melphalan and prednisone (MOMP) for the treatment of relapsed lymphoma in dogs

Veterinary and Comparative Oncology

Volumn 13, Issue 4, 2015, Pages 398-408

  Back, A R ^a   Schleis, S E ^a   Smrkovski, O A ^b   Lee, J ^b   Smith, A N ^a   Phillips, J C ^c  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c Animal Emergency Critical Care and Referral Center   (United States)

Author keywords

Canine; Chemotherapy; Lymphoma; Melphalan; Rescue

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; MELPHALAN; PREDNISONE; VINCRISTINE;

ANIMAL; DOG; DOG DISEASES; FEMALE; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; MORTALITY; RECURRENT DISEASE; SURVIVAL ANALYSIS; VETERINARY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOG DISEASES; DOGS; FEMALE; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MALE; MECHLORETHAMINE; MELPHALAN; PREDNISONE; RECURRENCE; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 84944281172     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/vco.12055     Document Type: Article

References (40)

1. Alvarez FJ, Kisseberth WC, Gallant SL and Couto CG. Dexamethasone, melphalan, actinomycin D, cytosine arbinoside (DMAC) Protocol for dogs with relapsed lymphoma. Journal of Veterinary Internal Medicine 2006; 20: 1178-1183.
2. Stone MS, Goldstein MA and Cotter SM. Comparison of two protocols for induction of remission in dogs with lymphoma. Journal of the American Animal Hospital Association 1991; 27: 315-321.
3. Zemann BI, Moore AS, Rand WM, Mason G, Ruslander DM, Frimberger AE, Wood CA, Gliatto J and Cotter SM. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. Journal of Veterinary Internal Medicine 1998; 12: 465-470.
4. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC and Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy for canine lymphoma. Journal of Veterinary Internal Medicine 1993; 7: 289-295.
5. Price GS, Page RL, Fischer BM, Levine JF and Gerig TM. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. Journal of Veterinary Internal Medicine 1991; 5: 259-262.
6. Carter RF, Harris CK, Withrow SJ, Valli VEO and Susaneck SJ. Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen. Journal of the American Animal Hospital Association 1987; 23: 587-596.
7. Boyce KL and Kitchell BE. Treatment of canine lymphoma with COPLA/LVP. Journal of the American Animal Hospital Association 2000; 36: 395-403.
8. Baskin CR, Couto CG and Wittum TE. Factors influencing first remission and survival in 145 dogs with lymphoma: a retrospective study. Journal of the American Animal Hospital Association 2000; 36: 404-409.
9. Piek CJ, Rutteman GR and Teske E. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. Veterinary Quarterly 1999; 21: 44-49.
10. Chun R, Garrett LD and Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2000; 14: 120-124.
11. Myers NC 3rd, Moore AS, Rand WM, Gliatto J and Cotter SM. Evaluation of a multidrug chemotherapy protocol (ACOPA-II) for the treatment of dogs with lymphoma. Journal of Veterinary Internal Medicine 1998; 11: 333-339.
12. Rassnick KM, Mauldin GE, Al-Sarraf R, Mauldin GN, Moore AS and Mooney SC. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000). Journal of Veterinary Internal Medicine 2002; 16: 576-580.
13. Lucroy MD, Phillips BS, Kraegel SA, Simonson ER and Madewell BR. Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma. Journal of Veterinary Internal Medicine 1998; 12: 325-329.
14. Moore AS, London CA, Wood CA, Williams LE, Cotter SM, L'Heureux DA and Frimberger AE. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. Journal of Veterinary Internal Medicine 1999; 13: 395-398.
15. Northrup NC, Gieger TL, Kosarek CE, Saba CF, LeRoy BE, Wall TM, Hume KR, Childress MO and Keys DA. Mechlorethamine, procarbazine and prednisone for the treatment of resistant lymphoma in dogs. Veterinary and Comparative Oncology 2009; 7: 38-44.
16. Fujino Y, Sawamura S, Kurakawa N, Hisasue M, Masuda K, Ohno K and Tsujimoto H. Treatment of chronic lymphocytic leukemia in three dogs with melphalan and prednisolone. The Journal of Small Animal Practice 2004; 45: 298-303.
17. Mikesch JH, Kuhlmann M, Demant A, Krug U, Thoennissen GB, Schmidt E, Kessler T, Schliemann C, Pohlen M, Mohr M, Evers G, Kohler G, Wessling J, Mesters R, Muller-Tidow C, Berdel WE, and Thoennissen NH. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Annals of Hematology 2013; 92: 1041-1048.
18. Nieto Y, Popat U, Anderlini P, Valdex B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R and Jones RB. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: Effect of the specific high-dose chemotherapy regimen on outcome. Biology of Blood and Marrow Transplantation 2013; 19: 410-417.
19. Owen LN. TNM Classification of Tumors in Domestic Animals. Geneva, World Health Organization, 1980: 21-25.
20. Veterinary Co-operative Oncology Group. common terminology criteria for adverse events (VCOG CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004; 2: 195-213.
21. th edn., SJ Withrow, DM Vail, and RL Page, eds., St. Louis, Elsevier Saunders, 2013: 127.
22. Petrie A and Watson P. Experimental design and clinical trials. In: Statistics for Veterinary and Animal Science. A Petrie and P Watson Eds., Oxford, Blackwell Publishing, 1999: 57.
23. Hodgson CD and Tannock IF. Guide to studies of diagnostic tests, prognostic factors, and treatments. In: The Basic Science of Oncology. 4 edn., IF Tannock, RP Hill, RG Bristow and L Harrington Eds., New York, McGraw-Hill, 2005: 497.
24. Brodsky EM, Mauldin GN, Lachowicz JL and Post GS. Asparaginase and MOPP treatment of dogs with lymphoma. Journal of Veterinary Internal Medicine 2009; 23: 578-584.
25. Vail DM and Thamm DH. Hematopoietic tumors. In: Texbook of Veterinary Internal Medicine. 6 edn., SJ Ettinger and EC Feldman Eds., St. Louis, MPO, Elsevier Saunders, 2005: 732-747.
26. Vail DM, Kisseberth WC, Obradovich JE, Moore FM, London CA, MacEwen EG and Ritter MA. Assessment of potential doubling time (Tpot), argyrophilic nucleorlar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma. Experimental Hematology 1996; 24: 807-815.
27. Ruslander DA, Gebhard DH, Tompkins MB, Grindem CB and Page RL. Immunophenotypic characterization of canine lymphoproliferative disorders. In Vivo 1997; 11: 169-172.
28. Moore AS, Leveille CR, Reimann KA, Shu H and Arias IM. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Investigation 1995; 13: 475-479.
29. Bergman PJ, Ogilvie GK and Powers BE. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. Journal of Veterinary Internal Medicine 1996; 10: 354-359.
30. Lee JJ, Hughes CS, Fine RL and Page RL. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 1996; 77: 1892-1898.
31. Ginn PE. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embeded normal and neoplastic canine tissues. Veterinary Clinical Pathology 1996; 33: 533-541.
32. Greenlee PG, Filippa DA, Quimby FW, Patnaik AK, Calvano SE, Matus RE, Kimmel M, Hurvitz AL and Lieberman PH. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990; 66: 480-490.
33. Fournel-Fleury C, Magnol JP, Bricaire P and Guelfi JF. Cytohistological and immunological classifications of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. Journal of Comparative Pathology 1997; 117: 35-59.
34. Appelbaum FR, Sale GE, Storb R, Charrier K, Deeg HJ, Graham T and Wulff JC. Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: classification, morphology, clinical presentation and response to chemotherapy. Journal of Hematology & Oncology 1984; 2: 151-168.
35. Teske E, van Heerde P, Rutteman GR, Kurzman ID, Moore PF and MacEwen EG. Prognostic factors for treatment of malignant lymphoma in dogs. Journal of the American Veterinary Medical Association 1994; 205: 1722-1728.
36. Fournel-Fleury C, Ponce F, Felman P, Blavier A, Bonnefont C, Chabanne L, Marchal T, Cadore JL, Goy-Thollot I, Ledieu D, Ghernati I and Magnol JP. Canine T-cell lymphomas: a morphological immunological and clinical study of 46 new cases. Veterinary Clinical Pathology 2002; 39: 92-109.
37. Wilkerson MJ, Dolce K, Koopman T, Shuman W, Chun R, Garrett L, Barber L and Avery A. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules. Veterinary Immunology and Immunopathology 2005; 106: 176-196.
38. Culmsee K, Simon D, Mischke R and Nolte I. Possibilities of flow cytometeric analysis for immunophenotypic characterization of canine lymphoma. Journal of Veterinary Medicine Series-A-physiology Pathology Clinical Medicine 2001; 49: 99-204.
39. Tew KD, Colvin OM and Jones RB. Clinical and high-dose alkylating agents. In: Cancer Chemotherapy and Biotherapy Principles and Practice. 4 edn., BA Chabner and DL Longo Eds., Philadelphia, Lippincott Williams and Wilkins, 2006: 283-309.
40. Bergman PJ. Multidrug resistance. In: Kirk's Current Veterinary Therapy XIII Small Animal Practice. JD Bonagura Ed., Philadelphia, WB Saunders Company, 2000: 479-482.